Evidence-Based Anticoagulation Choice for Acute Pulmonary Embolism
JAMA Network Open · 03.01.2025 · 8 (1) · e2452850
DOI: 10.1001/jamanetworkopen.2024.52850 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAMA Network Open, online erschienen am 03.01.2025. Verfasst von Brandon C Maughan und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Emergency Medicine, Oregon Health and Science University, Portland. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAMS NIH HHS, NICHD NIH HHS.
Abstract (Originalsprache)
Systemic anticoagulation is the foundation of treatment for most patients with pulmonary embolism (PE).Guidelines recommend that most patients hospitalized for acute PE who are treated with parenteral anticoagulation should receive a low molecular weight heparin (LMWH) rather than unfractionated heparin (UFH) because LMWH achieves therapeutic anticoagulation more quickly and is associated with fewer bleeding complications.[1][2][3] Despite this recommendation, the proportion of US patients with acute PE initially treated with UFH increased from 41.9% to 56.3% between 2011 and 2020, whereas less than 10% of similar patients in Europe were treated with UFH. 4 Faced with such contradictory data, Stubblefield and colleagues conducted a robust qualitative study of 46 emergency physicians, hospitalists, and interventionalists in the US to understand the factors associated with anticoagulation decisions for PE. 5 Among the authors' conclusions were that emergency and hospitalist physicians share misconceptions regarding anticoagulation and thrombolytic therapies for PE.Here we address several of these crucial misunderstandings and the imperative to update these practices.Heparin revolutionized the care of thromboembolic disease when it was first introduced to clinical care in the late 1930s, yet it is far from perfect.The action of UFH is affected by extensive binding to plasma proteins and vascular endothelial cells; minor UFH dose changes can produce dramatic swings in the intensity of anticoagulation due to its nonlinear and dose-dependent elimination.As a result, UFH infusions require frequent monitoring and dose adjustments.In contrast, LMWH and direct oral anticoagulants (DOACs) experience less protein binding, more predictable pharmacokinetics, and a more consistent anticoagulation effect.6 In their study, Stubblefield et al found several major themes behind the selection of UFH as an initial anticoagulant for acute PE.Three common misconceptions regarding
Autor:innen und Institutionen
- Department of Emergency Medicine, Oregon Health and Science University, Portland.
- Center for Vascular Emergencies, Department of Emergency Medicine, Mass General Brigham, Boston.
- Department of Emergency Medicine, Harvard Medical School, Boston, Massachusetts.
- Department of Emergency Medicine, University of California Davis, Davis.
Förderung
- NIAMS NIH HHS
- NICHD NIH HHS
Zitieren
APA
Maughan, B. C., Kabrhel, C., & Jarman, A. F. (2025). Evidence-Based Anticoagulation Choice for Acute Pulmonary Embolism. JAMA Network Open, 8(1), e2452850. https://doi.org/10.1001/jamanetworkopen.2024.52850
Vancouver
Maughan BC, Kabrhel C, Jarman AF. Evidence-Based Anticoagulation Choice for Acute Pulmonary Embolism. JAMA Network Open. 2025;8(1):e2452850. doi:10.1001/jamanetworkopen.2024.52850
BibTeX
@article{Maughan2025,
author = {Maughan, Brandon C and Kabrhel, Christopher and Jarman, Angela F},
title = {Evidence-Based Anticoagulation Choice for Acute Pulmonary Embolism},
journal = {JAMA Network Open},
year = {2025},
volume = {8},
number = {1},
pages = {e2452850},
doi = {10.1001/jamanetworkopen.2024.52850}
}
EUVIMED